日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study

前瞻性随机SUCCESS A研究中遗传性乳腺癌易感变异与预后的关系

Hein, A; Rack, B; Li, L; Ekici, A B; Reis, A; Lux, M P; Cunningham, J M; Rübner, M; Fridley, B L; Schneeweiss, A; Tesch, H; Lichtenegger, W; Fehm, T; Heinrich, G; Rezai, M; Beckmann, M W; Janni, W; Weinshilboum, R M; Wang, L; Fasching, P A; Häberle, L

Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial

一项评估 FEC-Doc 和 FEC-Doc 联合吉西他滨作为高危早期乳腺癌辅助治疗的 III 期研究的毒性评估:SUCCESS-A 试验

Schröder, L; Rack, B; Sommer, H; Koch, J G; Weissenbacher, T; Janni, W; Schneeweiss, A; Rezai, M; Lorenz, R; Jäger, B; Schramm, A; Häberle, L; Fasching, P A; Friedl, T W P; Beckmann, M W; Scholz, C

Impact of Age, Obesity and Smoking on Patient Satisfaction with Breast Implant Surgery - A Unicentric Analysis of 318 Implant Reconstructions after Mastectomy

年龄、肥胖和吸烟对乳房植入手术患者满意度的影响——一项对318例乳房切除术后植入重建手术的单中心分析

Kern, P; Zarth, F; Kimmig, R; Rezai, M

Evaluation of two different analytical methods for circulating tumor cell detection in peripheral blood of patients with primary breast cancer.

评价两种不同的分析方法在原发性乳腺癌患者外周血中循环肿瘤细胞检测中的应用

Jaeger B A S, Jueckstock J, Andergassen U, Salmen J, Schochter F, Fink V, Alunni-Fabbroni M, Rezai M, Beck Th, Beckmann M W, Friese K, Friedl T W P, Janni W, Rack B

Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study

评估接受来曲唑治疗的激素受体阳性绝经后乳腺癌患者的治疗管理和患者依从性:Evaluate™ 研究

Fasching, P A; Fehm, T; Kellner, S; de Waal, J; Rezai, M; Baier, B; Baake, G; Kolberg, H-C; Guggenberger, M; Warm, M; Harbeck, N; Würstlein, R; Deuker, J-U; Dall, P; Richter, B; Wachsmann, G; Brucker, C; Siebers, J W; Fersis, N; Kuhn, T; Wolf, C; Vollert, H-W; Breitbach, G-P; Janni, W; Landthaler, R; Kohls, A; Rezek, D; Noesslet, T; Fischer, G; Henschen, S; Praetz, T; Heyl, V; Kühn, T; Krauß, T; Thomssen, C; Kümmel, S; Hohn, A; Tesch, H; Mundhenke, C; Hein, A; Rauh, C; Bayer, C M; Jacob, A; Schmidt, K; Belleville, E; Hadji, P; Wallwiener, D; Grischke, E-M; Beckmann, M W; Brucker, S Y

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

21基因复发评分检测会影响ER阳性、淋巴结阴性和淋巴结阳性早期乳腺癌的辅助治疗建议,从而导致化疗方案根据风险进行调整。

Eiermann, W; Rezai, M; Kümmel, S; Kühn, T; Warm, M; Friedrichs, K; Schneeweiss, A; Markmann, S; Eggemann, H; Hilfrich, J; Jackisch, C; Witzel, I; Eidtmann, H; Bachinger, A; Hell, S; Blohmer, J